Mukka Proteins Limited issues ₹470 million warrants
Mukka Proteins Limited (NSE: MUKKA) – Announcement Summary (19 Jun 2026)
Introduction
Mukka Proteins Limited filed a new XBRL announcement with the NSE on 12 June 2026, detailing a preferential issue of fully convertible warrants. The filing provides the complete terms of the fund‑raising, board approvals, and the list of participating investors.
Key Highlights of the Preferential Issue
Transaction Overview
- Type of securities: Fully Convertible Warrants (convertible into equity shares within 18 months of allotment).
- Total amount to be raised: ₹ 470 million.
- Number of warrants to be issued: 20 million (₹ 23 per warrant).
- Issue price disclosed: ₹ 23 per warrant (actual price intended to be ₹ 23.50, but a technical error limited the filing to ₹ 23).
Share Capital Impact
| Metric | Pre‑Issue | Post‑Issue |
|---|---|---|
| Paid‑up share capital (shares) | 300,000,000 | 320,000,000 |
| Shares paid up after preferential issue | – | 320,000,000 |
| Outcome of subscription (shares allotted) | – | 320,000,000 |
Investor Participation
- Number of investors: 15
- Names of investors (selected):
- Irfan Chapra, Reshma Chapra, Vishal Maniar, Payal Maniar, Jasbir Singh Batra, Ranjit Singh Batra, Gurminder Kaur, Jasbir Singh & Sons HUF, Sarabdeep Kaur Darshan Singh, Ranjit Singh & Sons HUF, Multiplex Capital Limited, Hiren Hiralal Shiyal, B A Abdul Nasir, Soofikhan Kalander Asif, B H Rizwan.
Board and Regulatory Approvals
- Board meeting approving fund‑raising: 12 June 2026 (meeting time 11:10 – 17:00).
- Prior intimation to the exchange: Submitted on 9 June 2026 (compliant with SEBI requirements).
- SEBI Circular 9 (Sept 2015) compliance: Confirmed true.
- Date of AGM/E‑GM/Postal ballot: Fixed for 12 July 2026.
- Record/book closure: Not fixed by the company (no date provided).
Additional Terms
- Conversion window: Warrants convertible into equity shares within 18 months from the allotment date.
- Tenure of instrument lapse date: 12 January 2028 (no change to conversion date).
- No change made to the conversion date; the date is currently not available in the filing.
Regulatory & Compliance Summary
- The issuance is fully disclosed as per SEBI (ICDR) regulations for determining floor price.
- The board decided the mode of fund raising (preferential issue of convertible warrants).
- No cancellation or termination of the proposal has been announced.
Investor Takeaways
- The preferential issue will increase Mukka Proteins’ paid‑up share capital by 20 million shares, raising ₹ 470 million for the company.
- The convertible nature of the warrants provides investors the option to become equity shareholders within a defined period, potentially diluting existing shareholders if conversion occurs.
- All procedural requirements—including board approval, prior intimation, and SEBI circular compliance—have been satisfied, indicating a regulatory‑clean fund‑raising process.
This summary reflects only the information disclosed in the XBRL announcement filed on 12 June 2026.
Mukka Proteins is raising about ₹470 million through fully convertible warrants, which will dilute existing shareholders by roughly 6.7%. In the short run the stock may dip modestly, but the capital could support growth, limiting any prolonged downside.
Sign in for impact outlook, horizons, comparables, and full intelligence analysis.
Forecast from comparable, historic events. Not investment advice.
Original Source Document
View the original exchange filing or announcement.
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka